Drug Trial Radar · NCT01072630
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: Apr 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
492
Actual
Start
Mar 2010
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Feb 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.
Conditions
- Depression
Interventions
ArmodafinilDrug
Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
PlaceboDrug
Matching Placebo, also in tablet form taken orally, once daily in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)Time frame: Day 0 (baseline), Week 8
Locations
92 sites in 10 countries. Site status is shown where the registry gives one.
Birmingham Psychiatry Pharmaceutical Studies, Inc
Birmingham, Alabama
South Coast Medical Associates/SC Clinical Trials, Inc.
Anaheim, California
Comprehensive NeuroScience
Cerritos, California
Sun Valley Behavioral Medical
Imperial, California
North County Clinical Research
Oceanside, California
CNRI Los Angeles LLC
Pico Rivera, California
CNRI-San Diego LLC
San Diego, California
Clinical Innovations Inc.
Santa Ana, California
Schuster Medical Research Institute
Sherman Oaks, California
Stanford University Medical Center
Stanford, California
Viking Clinical Research Center
Temecula, California
Comprehensive NeuroScience
Washington D.C., District of Columbia
Scientific Clinical Research, Inc.
Aventura, Florida
Florida Clinical Research Center
Bradenton, Florida
Clinical Neuroscience Solutions Inc
Jacksonville, Florida
Fidelity Clinical Research
Lauderhill, Florida
Compass Research, LLC
Orlando, Florida
Stedman Clinical Trials, LLC
Tampa, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Carman Research
Smyrna, Georgia
Hawaii Clinical Research Center
Honolulu, Hawaii
Midwest Center for Neurobehavioral Medicine
Oakbrook Terrace, Illinois
CNS - Comprehensive Neuro Science
Park Ridge, Illinois
Community Research
Crestview Hills, Kentucky
AccelRx Research
Fall River, Massachusetts
Mayo College of Medicine
Rochester, Minnesota
Precise Research Centers
Flowood, Mississippi
CRI Worldwide, LLC
Mount Laurel, New Jersey
Behavioral Medical Research of Brooklyn
Brooklyn, New York
Fieve Clinical Services, Inc.
New York, New York
Medical and Behavioral Health Research
New York, New York
Behavioral Medical Research of Staten Island
Staten Island, New York
Richmond Behavioral Associates
Staten Island, New York
North Coast Clinical Trials, Inc.
Beachwood, Ohio
Neuro-Behavioral Clinical Research, Inc
Canton, Ohio
IPS Research Company
Oklahoma City, Oklahoma
Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.)
Portland, Oregon
Lehigh Center for Clinical Research
Allentown, Pennsylvania
Belmont Center for Comprehensive Treatment
Philadelphia, Pennsylvania
FutureSearch Trials of Neurology
Austin, Texas
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.